Guangdong Hybribio Biotech Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 5.65%

Guangdong Hybribio Biotech Co Ltd (300639) has an Asset Resilience Ratio of 5.65% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 300639 liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥242.05 Million

≈ $35.42 Million USD Cash + Short-term Investments

Total Assets

CN¥4.28 Billion

≈ $626.65 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Guangdong Hybribio Biotech Co Ltd's Asset Resilience Ratio has changed over time. See Guangdong Hybribio Biotech Co Ltd (300639) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Guangdong Hybribio Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Guangdong Hybribio Biotech Co Ltd (300639) market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥242.05 Million	5.65%
Total Liquid Assets	CN¥242.05 Million	5.65%

Asset Resilience Insights

Limited Liquidity: Guangdong Hybribio Biotech Co Ltd maintains only 5.65% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Guangdong Hybribio Biotech Co Ltd Industry Peers by Asset Resilience Ratio

Compare Guangdong Hybribio Biotech Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Sonic Healthcare Ltd AU:SHL	Diagnostics & Research	0.13%
Eurofins-Cerep SA PA:ALECR	Diagnostics & Research	6.56%
Inoviq Ltd AU:IIQ	Diagnostics & Research	56.29%
Bcal Diagnostics Ltd AU:BDX	Diagnostics & Research	0.00%
Imagion Biosystems Ltd AU:IBX	Diagnostics & Research	150.16%
Integral Diagnostics Ltd AU:IDX	Diagnostics & Research	0.03%
Australian Clinical Labs Ltd AU:ACL	Diagnostics & Research	4.11%
Monash Ivf Group Ltd AU:MVF	Diagnostics & Research	1.60%

Annual Asset Resilience Ratio for Guangdong Hybribio Biotech Co Ltd (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Guangdong Hybribio Biotech Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	5.41%	CN¥250.29 Million ≈ $36.62 Million	CN¥4.62 Billion ≈ $676.49 Million	+0.05pp
2023-12-31	5.36%	CN¥307.05 Million ≈ $44.93 Million	CN¥5.73 Billion ≈ $837.86 Million	-0.39pp
2022-12-31	5.75%	CN¥387.06 Million ≈ $56.64 Million	CN¥6.73 Billion ≈ $984.98 Million	-10.25pp
2021-12-31	16.00%	CN¥677.14 Million ≈ $99.09 Million	CN¥4.23 Billion ≈ $619.18 Million	-14.10pp
2020-12-31	30.10%	CN¥860.00 Million ≈ $125.85 Million	CN¥2.86 Billion ≈ $418.06 Million	+29.72pp
2019-12-31	0.39%	CN¥5.00 Million ≈ $731.66K	CN¥1.30 Billion ≈ $189.79 Million	--

pp = percentage points

About Guangdong Hybribio Biotech Co Ltd

SHE:300639 China Diagnostics & Research

Market Cap

$573.30 Million

CN¥3.92 Billion CNY

Market Cap Rank

#11834 Global

#3628 in China

Share Price

CN¥6.06

Change (1 day)

-1.14%

52-Week Range

CN¥5.20 - CN¥8.81

All Time High

CN¥19.74